Better Health for All

Nautilus Biotechnology's principal offering is a single-molecule protein analysis platform designed to advance drug development and precision medicine.

The platform is intended to accelerate the discovery of new drug targets, improve patient stratification, and enhance the understanding of disease mechanisms. It is applied in research for various diseases, including Alzheimer's, Angelman syndrome, cancer, and autoimmune disorders, with the potential for improved diagnostics and treatments. The platform can detect approximately 800 proteoforms of the Alzheimer's disease-associated protein tau in early studies. While the platform is a tool for health research and discovery, there is no evidence that it currently delivers direct, measurable health benefits to patients or constitutes a 'product portfolio' with established health outcomes. The platform is being used to study tau proteoforms in organoid models from frontotemporal dementia patients, which could potentially impact research on vulnerable populations, but there is no evidence of equitable access or reach to these populations.

Fair Pay & Worker Respect

No quantitative data is available to assess Nautilus Biotechnology against the Fair Pay & Worker Respect KPIs. While employee reviews mention mixed sentiment regarding compensation, work-life balance, and management, and some praise benefits like medical, dental, and vision coverage, these are qualitative observations and do not provide specific metrics required by the rubric.

CEO total compensation was reported at $1.96 million, but median employee compensation was not provided, preventing calculation of the CEO-to-median pay ratio. The company conducted layoffs affecting 16% of its workforce (25 employees), reducing headcount to 133, but this is not voluntary turnover. A letter was received from the Nasdaq Stock Market Listing Qualifications Staff, but details were not provided to determine if it relates to labor violations. No information on living wage coverage, collective bargaining, safety incidents, pay equity, worker engagement scores, labor violations, insecure contract share, or health insurance coverage percentages is available.

Honest & Fair Business

No specific, concrete data points were found in the provided articles to assess Nautilus Biotechnology, Inc. against any of the 'Honest & Fair Business' KPIs.

The articles explicitly state a lack of data on ethical metrics or were throttled, preventing information retrieval.

Kind to Animals

Nautilus Biotechnology, Inc. uses animal models for product testing, including in mouse models for Alzheimer's disease and cryptococcal infection, and its Belerofon product is tested in animal models.

There is no explicit animal testing policy mentioned. The company detected over 3,000 host proteins and 160 fungal proteins in mice during cryptococcal infection research. There is no transparent reporting on the total number of animals used annually or any reduction targets. While the company collaborates with Professor Birgit Schilling, who presented data generated on the Nautilus Platform using a mouse model, and mentions molecular pharming using plants as an alternative to animal-based production, there is no evidence of formal collaboration on industry-wide animal-free standards or significant resource commitment to such initiatives.

Safe & Smart Tech

Nautilus Biotechnology, Inc.'s privacy policy, updated March 2023, states that users can modify and delete their information by contacting the company directly.

The company's 2022 fiscal year-end report and the March 2023 privacy policy mention compliance with various privacy regulations, including HIPAA, GDPR, CCPA, and Nevada and California privacy laws. However, no specific details on the effectiveness or scope of this compliance are provided, nor are there any mentions of regulatory actions, violations, or fines.